David A. Siegel Graphite Bio, Inc. Transaction History

Two Sigma Advisers, LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$2.24 - $2.66 $60,480 - $71,820	-27,000 Reduced 16.64%	135,300 $354,000
Q3 2023 Nov 14, 2023	BUY	$2.18 - $2.77 $6,758 - $8,587	3,100 Added 1.95%	162,300 $402,000
Q2 2023 Aug 14, 2023	SELL	$2.47 - $3.38 $122,512 - $167,648	-49,600 Reduced 23.75%	159,200 $413,000
Q1 2023 May 15, 2023	SELL	$1.85 - $3.21 $85,840 - $148,944	-46,400 Reduced 18.18%	208,800 $511,000
Q4 2022 Feb 14, 2023	SELL	$2.82 - $3.59 $31,584 - $40,208	-11,200 Reduced 4.2%	255,200 $847,000
Q3 2022 Nov 14, 2022	BUY	$2.82 - $4.24 $75,294 - $113,208	26,700 Added 11.14%	266,400 $844,000
Q2 2022 Aug 15, 2022	BUY	$2.14 - $5.23 $512,958 - $1.25 Million	239,700 New	239,700 $659,000

637K

Ticker GRPH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,211,200
Description
Graphite Bio, Inc., a clinical-stage gene editing company, engages in developing therapies for serious and life-threatening diseases in the United States. It offers GPH101, a gene-edited autologous hematopoietic stem cell product candidate to directly correct the mutation that causes sickle cell disease and restore normal adult hemoglobin expres...

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.